Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 27;26(10):e1786–e1799. doi: 10.1002/onco.13887

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published 2021. This article is a U.S. Government work and is in the public domain in the USA. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Timeline of PD‐[L]1 inhibitor approvals. Notes : approvals for new indications are shown in the figure. Conversions from accelerated to regular approval are not shown. Abbreviations: CRC, colorectal cancer; cutaneous squamous cell carcinoma; ESCC, esophageal squamous cell carcinoma; GEJ, gastroesophageal junction; HCC, hepatocellular carcinoma; HL, Hodgkin lymphoma; HNSCC, head and neck squamous cell carcinoma; MSI‐h, microsatellite instability high; NSCLC, non‐small cell lung cancer; PMBCL, primary mediastinal B cell lymphoma; RCC, renal cell carcinoma; SCLC, extensive‐stage small cell lung cancer; TMB, tumor mutation burden‐high; TNBC, triple‐negative breast cancer.